FindTrial
Sign In

The diagnoistic power of Fecal calprotetin to assess inflammatory bowel disease activity in China

The diagnoistic power of Fecal calprotetin to assess inflammatory bowel disease activity in China

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDT-14005066
Enrollment
Unknown
Registered
2014-08-04
Start date
2014-04-22
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory bowel disease

Interventions

Gold Standard:
Index test:

Sponsors

Department of Gastroenterology, Nanfang Hospital, SouthernMedical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Diagnosed inflammatory bowel disease, complete ileocolonoscopy; age 18-85 years, fecal samples delivered from 3 days to 1 day before ileocolonoscopy.

Exclusion criteria

Exclusion criteria: patients who were considered to have intestinal tuberculosis, indeterminate or microscopic colitis, infective enterocolitis, or Behc'et disease; regular intake of aspirin and/or non-steroidal antiinflammatory drugs (NSAID); urinary incontinence; pregnancy; patients who had undergone intestinal resection due to trauma.

Design outcomes

Primary

MeasureTime frame
fecal calprotectin;—

Countries

China

Contacts

Public ContactBiao Nie
niebiao2@hotmail.com+86 020 62787934

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026